← All stocks

bioAffinity Technologies, Inc.

BIAF Balanced
CIK 0001712762 #5518 in the set updated 17 Sep 2026
Bought (120 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$0.00
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 0 sales
Net
$0.00
$0.00 against sales at will

By person

15 insiders · 40 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Anderson Robert A.
Director
(1)
$0.00
163,936
DIAMOND STUART
Director
(1)
$0.00
99,088
Edwards James Michael
VP and CFO
(1)
$0.00
120,128
+2,028%
GIRGENTI STEVEN
Executive Chairman
(1)
$0.00
1,089,017
+393.0%
KNIGHT PETER S
Director
(1)
$0.00
117,455
+722.2%
Rubin Gary D
Director
(1)
$0.00
1,714,415
+105.2%
Zannes Maria
President & CEO
(1)
$0.00
280,359
+7,751%
Perlmutter Nathan M
10% owner
327,909
+97.4%
Meghji Mohsin Y
Director
109,737
+284.1%
Dougherty Michael Philip
Chief Financial Officer
84,203
Joyce Roby
Director
66,615
Zannes Timothy P
Secretary, EVP, Gen. Counsel
54,765
Platt Jamie
Director
54,748
Rebel Vivienne I
Chief Sci. & Med. Officer, EVP
46,228
+547.3%
Reveles Xavier Trinidad
Chief Operating Officer
41,943
+1,059%

No percentages here. This company's share count has moved by a factor of 6.3 over the window, from 4,498,675 to 28,468,612 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Edwards James Michael
1 Sep 2022
Chief Financial Officer
Buy
2,448
no price
Rubin Gary D
31 Aug 2022
Director
Buy indirect
16,326
no price
GIRGENTI STEVEN
31 Aug 2022
Executive Chairman
Buy
40,916
no price
Zannes Maria
31 Aug 2022
President, CEO
Buy
16,326
no price
DIAMOND STUART
31 Aug 2022
Director
Buy
4,081
no price
Anderson Robert A.
31 Aug 2022
Director
Buy
4,081
no price
KNIGHT PETER S
31 Aug 2022
Director
Buy
8,163
no price

What was left out

Form 4 filings counted 62
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 7
Shares from compensation/vesting 3,174,458
History held since 21 Oct 2022